RLAY
Relay Therapeutics, Inc. NASDAQ Listed Jul 16, 2020$15.88
+2.06%
vs $15.56
Mkt Cap $2.7B
52w Low $3.19
93.2% of range
52w High $16.80
50d MA $14.17
200d MA $9.31
P/E (TTM)
-9.9x
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.1x
ROE
-48.8%
P/FCF
-11.6x
RSI (14)
62.40
ATR (14)
$0.97
Beta
1.58
50d MA
$14.17
200d MA
$9.31
Avg Volume
4.5M
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
399 Binney Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -0.35 | -0.41 | -17.1% | 13.00 | +0.2% | -0.6% | -3.2% | +2.0% | +0.7% | +0.6% | — |
| Feb 26, 2026 | AMC | -0.38 | -0.32 | +15.8% | 9.16 | +5.2% | +12.0% | -4.6% | +0.6% | +3.0% | -5.0% | — |
| Nov 6, 2025 | AMC | -0.39 | -0.43 | -10.3% | 6.53 | -5.4% | -7.4% | +2.0% | +1.9% | -1.9% | +4.5% | — |
| Aug 7, 2025 | AMC | -0.49 | -0.41 | +16.3% | 3.49 | -8.9% | -7.7% | +0.9% | +3.1% | +2.1% | -0.9% | — |
| May 5, 2025 | AMC | -0.50 | -0.46 | +8.0% | 3.32 | -0.9% | -5.1% | -6.3% | +1.7% | +0.0% | +3.7% | — |
| Feb 26, 2025 | AMC | -0.57 | -0.45 | +21.1% | 3.75 | -13.3% | -13.3% | +4.9% | -6.2% | -0.3% | +6.3% | — |
| Nov 6, 2024 | AMC | -0.77 | -0.63 | +18.2% | 6.25 | +1.3% | -1.8% | +1.0% | -0.6% | -3.6% | -2.2% | — |
| Aug 6, 2024 | AMC | -0.73 | -0.69 | +5.5% | 7.19 | -3.1% | -7.9% | +2.7% | -1.5% | -2.8% | +0.8% | — |
| May 2, 2024 | AMC | -0.70 | -0.62 | +11.4% | 7.08 | +23.0% | -0.6% | +0.3% | -4.5% | -3.4% | -3.1% | — |
| Feb 22, 2024 | AMC | -0.76 | -0.67 | +11.8% | 10.57 | +2.5% | -5.4% | +1.6% | +1.3% | -2.0% | -0.6% | — |
| Nov 2, 2023 | AMC | -0.83 | -0.54 | +34.9% | 7.40 | +13.0% | +1.6% | +8.1% | +0.2% | -3.8% | -3.4% | — |
| Aug 8, 2023 | AMC | -0.78 | -0.81 | -3.8% | 11.17 | +4.9% | +0.1% | -2.3% | -1.7% | +3.9% | -4.8% | — |
| May 4, 2023 | AMC | -0.70 | -0.78 | -11.4% | 11.22 | -6.1% | +0.4% | -4.0% | -1.8% | +0.8% | -3.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.03 | $13.17 | +1.1% | -3.5% | +3.1% | -1.9% | +2.9% | -0.7% |
| Apr 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $14.95 | $14.79 | -1.1% | -12.8% | -3.5% | +3.1% | -1.9% | +2.9% |
| Apr 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.95 | $14.79 | -1.1% | -12.8% | -3.5% | +3.1% | -1.9% | +2.9% |
| Apr 28 | Goldman Sachs | Maintains | Buy → Buy | — | $14.95 | $14.79 | -1.1% | -12.8% | -3.5% | +3.1% | -1.9% | +2.9% |
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $14.95 | $14.79 | -1.1% | -12.8% | -3.5% | +3.1% | -1.9% | +2.9% |
| Apr 8 | Barclays | Maintains | Overweight → Overweight | — | $13.48 | $14.00 | +3.9% | +7.6% | +3.4% | -0.4% | +2.1% | -3.3% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.91 | $10.04 | +1.3% | -0.9% | -3.9% | +1.7% | +5.4% | -5.1% |
| Mar 17 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.13 | $10.06 | -0.7% | +1.3% | -3.2% | +0.7% | -0.9% | -0.9% |
| Mar 17 | Citizens | Maintains | Market Outperform → Market Outperform | — | $10.13 | $10.06 | -0.7% | +1.3% | -3.2% | +0.7% | -0.9% | -0.9% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $10.55 | $11.00 | +4.3% | -1.8% | -2.2% | +1.3% | -3.2% | +0.7% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.16 | $9.64 | +5.2% | +12.0% | -4.6% | +0.6% | +3.0% | -5.0% |
| Jan 26 | Oppenheimer | Upgrade | Perform → Outperform | — | $7.43 | $7.67 | +3.2% | +2.2% | +12.0% | -10.0% | +0.8% | -0.6% |
| Dec 12 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $7.79 | $8.60 | +10.4% | +3.1% | +5.6% | +0.0% | -5.3% | +1.2% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.53 | $6.18 | -5.4% | -7.4% | +2.0% | +1.9% | -1.9% | +4.5% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.51 | $3.50 | -0.3% | +0.9% | +0.8% | +3.4% | -2.7% | +1.9% |
| Aug 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $3.49 | $3.18 | -8.9% | -7.7% | +0.9% | +3.1% | +2.1% | -0.9% |
| May 7 | Guggenheim | Maintains | Buy → Buy | — | $3.15 | $3.18 | +1.0% | -6.3% | +1.7% | +0.0% | +3.7% | -9.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.48 | $3.45 | -0.9% | -0.6% | -5.5% | +6.1% | +5.5% | -6.8% |
| Feb 27 | Stifel | Maintains | Buy → Buy | — | $3.75 | $3.25 | -13.3% | -13.3% | +4.9% | -6.2% | -0.3% | +6.3% |
| Feb 27 | Goldman Sachs | Maintains | Buy → Buy | — | $3.75 | $3.25 | -13.3% | -13.3% | +4.9% | -6.2% | -0.3% | +6.3% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.78 | $4.77 | -0.2% | -9.0% | -12.4% | +13.4% | +3.2% | +4.5% |
| Dec 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.98 | $4.98 | +0.0% | -4.0% | -1.5% | +2.8% | -7.0% | -6.7% |
| Dec 5 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.39 | $4.41 | +0.5% | -2.5% | +7.7% | +2.0% | -5.7% | +12.4% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.39 | $4.41 | +0.5% | +0.0% | -2.5% | +7.7% | +2.0% | -5.7% |
| Dec 4 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.39 | $4.41 | +0.5% | +0.0% | -2.5% | +7.7% | +2.0% | -5.7% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.14 | $6.15 | +0.2% | +1.0% | -0.6% | -3.6% | -2.2% | -3.6% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.73 | -1.0% | -0.7% | -0.1% | +0.9% | -2.4% | +1.4% |
| Sep 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.11 | $8.12 | +0.1% | -6.3% | -0.3% | +3.7% | -4.6% | -0.9% |
| Sep 16 | Stifel | Maintains | Buy → Buy | — | $7.60 | $8.15 | +7.2% | +6.7% | -6.3% | -0.3% | +3.7% | -4.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.60 | $8.15 | +7.2% | +6.7% | -6.3% | -0.3% | +3.7% | -4.6% |
| Sep 10 | Jefferies | Upgrade | Hold → Buy | — | $9.51 | $10.00 | +5.2% | -5.4% | -13.8% | -1.8% | -0.3% | +6.7% |
| Sep 10 | Oppenheimer | Downgrade | Outperform → Perform | — | $9.51 | $10.00 | +5.2% | -5.4% | -13.8% | -1.8% | -0.3% | +6.7% |
| Sep 10 | JP Morgan | Maintains | Overweight → Overweight | — | $9.51 | $10.00 | +5.2% | -5.4% | -13.8% | -1.8% | -0.3% | +6.7% |
| Sep 10 | Barclays | Maintains | Overweight → Overweight | — | $9.51 | $10.00 | +5.2% | -5.4% | -13.8% | -1.8% | -0.3% | +6.7% |
| Sep 10 | BofA Securities | Maintains | Buy → Buy | — | $9.51 | $10.00 | +5.2% | -5.4% | -13.8% | -1.8% | -0.3% | +6.7% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $7.19 | $6.97 | -3.1% | -7.9% | +2.7% | -1.5% | -2.8% | +0.8% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.19 | $6.97 | -3.1% | -7.9% | +2.7% | -1.5% | -2.8% | +0.8% |
| Jul 26 | Barclays | Maintains | Overweight → Overweight | — | $9.06 | $9.00 | -0.7% | -1.3% | -8.1% | +0.6% | -0.6% | -2.8% |
| Jul 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.90 | $8.56 | -3.8% | -2.6% | -0.8% | +2.3% | +7.7% | -5.8% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.98 | $8.31 | -7.5% | -0.9% | -2.6% | -0.8% | +2.3% | +7.7% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.27 | $7.23 | -0.6% | +8.7% | -4.7% | -4.0% | +8.4% | -0.1% |
| May 10 | Barclays | Upgrade | Equal Weight → Overweight | — | $6.31 | $6.78 | +7.4% | +1.7% | +0.0% | -0.9% | +6.9% | -4.3% |
| May 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.04 | $7.08 | +0.6% | +0.3% | -4.5% | -3.4% | -3.1% | +1.7% |
| May 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.04 | $7.08 | +0.6% | +0.3% | -4.5% | -3.4% | -3.1% | +1.7% |
| Feb 22 | Stifel | Maintains | Buy → Buy | — | $10.48 | $10.75 | +2.6% | +0.9% | -5.4% | +1.6% | +1.3% | -2.0% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.37 | $9.31 | -0.6% | +1.3% | +0.4% | +5.8% | -1.2% | +1.8% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.15 | $8.20 | +0.6% | -3.8% | -3.4% | +1.2% | +0.7% | +7.1% |
| Oct 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.93 | $6.93 | -0.1% | +7.7% | -5.2% | -4.1% | -0.3% | -5.2% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.44 | $10.41 | -0.3% | -0.9% | +2.3% | +0.8% | -0.9% | +1.0% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $11.17 | $11.72 | +4.9% | +0.1% | -2.3% | -1.7% | +3.9% | -4.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | 17,717 | $12.86 | $228K | 195,178 | -4.54% | +4.92% |
| Apr 28, 2026 | Bergstrom Donald A | President, R&D | Sell | 1,490 | $14.79 | $22K | 418,557 | -1.85% | -3.17% |
| Apr 28, 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | 972 | $14.79 | $14K | 212,895 | -1.85% | -3.17% |
| Apr 28, 2026 | Rahmer Peter | See remarks | Sell | 753 | $14.79 | $11K | 275,857 | -1.85% | -3.17% |
8-K
Relay Therapeutics, Inc. -- 8-K Filing
Relay Therapeutics completed a registered direct offering of common stock, with the prospectus supplement dated May 20, 2026 establishing final terms for the capital raise.
May 21
8-K · 8.01
!! High
Relay Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 19
8-K · 8.01
!! High
Relay Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Relay Therapeutics announced positive Phase 1/2 data for its zovegalisib triplet combination and plans to advance zovegalisib plus atirmociclib into Phase 3 testing for PI3K-mutated HR+/HER2- metastatic breast cancer.
Apr 27
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Relay Therapeutics' PI3K inhibitor shows clinical progress in advanced breast cancer combination trials, potentially supporting future regulatory approval and revenue growth if efficacy data continues strengthening.
Mar 16
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Relay Therapeutics' board gained flexibility to schedule annual shareholder meetings without advance notice restrictions, potentially reducing shareholder participation opportunities and limiting governance transparency.
Mar 11
8-K
Relay Therapeutics, Inc. -- 8-K Filing
Relay Therapeutics reported 2025 full-year results and provided 2026 guidance, demonstrating disciplined execution as a clinical-stage precision medicine company advancing oncology and genetic disease therapies.
Feb 26
8-K · 8.01
!! High
Relay Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Relay Therapeutics' zovegalisib received FDA Breakthrough Therapy designation combined with fulvestrant for PIK3CA-mutant HR+/HER2- breast cancer, accelerating development and potentially expediting market approval timelines.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Sb Investment Advisers (Uk) Ltd | 27,904,963 | $278M | New | Mar 2026 |
| 2 | Bellevue Group Ag | 7,795,242 | $78M | Reduced | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 7,387,465 | $74M | New | Mar 2026 |
| 4 | Fmr Llc | 3,695,431 | $37M | Added | Mar 2026 |
| 5 | Morgan Stanley | 4,036,928 | $34M | Added | Dec 2025 |
| 6 | Mpm Bioimpact Llc | 2,359,586 | $23M | Added | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 1,937,695 | $19M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 1,863,565 | $19M | New | Mar 2026 |
| 9 | Northern Trust Corp | 1,675,387 | $17M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 1,369,149 | $14M | Reduced | Mar 2026 |
| 11 | Alphabet Inc. | 1,568,753 | $13M | — | Dec 2025 |
| 12 | Aqr Capital Management Llc | 1,290,032 | $13M | Added | Mar 2026 |
| 13 | Foresite Capital Management Iv, Llc | 1,000,000 | $10M | — | Mar 2026 |
| 14 | Marshall Wace, Llp | 941,825 | $9M | New | Mar 2026 |
| 15 | Kalehua Capital Management Llc | 901,457 | $9M | — | Mar 2026 |
| 16 | Panagora Asset Management Inc | 818,041 | $8M | New | Mar 2026 |
| 17 | Woodline Partners Lp | 679,342 | $7M | — | Mar 2026 |
| 18 | Renaissance Technologies Llc | 673,599 | $7M | Added | Mar 2026 |
| 19 | Invesco Ltd. | 669,874 | $7M | Reduced | Mar 2026 |
| 20 | Arrowstreet Capital, Limited Partnership | 668,289 | $7M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.72B
Enterprise Value
$2.17B
P/E (TTM)
-9.86x
Forward P/E
—
PEG Ratio
0.17x
P/B
4.81x
P/S
177.45x
P/FCF
-11.55x
EV/EBITDA
—
Shares Out
171.6M
Financials (TTM)
Revenue
$15.4M
Net Income
-$276.5M
EBITDA
-$272.9M
Free Cash Flow
-$235.9M
Op Cash Flow
-$235.5M
EPS Basic
$-1.61
EPS Diluted
$-1.61
EPS Forward
$-1.53
Gross Margin
76.8%
Op Margin
-1971.6%
Net Margin
-1800.6%
Balance Sheet
Total Assets
$621.3M
Total Liab.
$54.3M
Total Equity
$567.1M
Cash
$554.5M
LT Debt
$0
Book Value/Sh
$3.30
Debt/Equity
0.06x
Current Ratio
22.61
Quick Ratio
22.61
Returns & Growth
ROE
-48.8%
ROA
-44.5%
ROIC
-50.5%
Rev Growth YoY
+53.4%
EPS Growth YoY
+31.8%
Price Returns
2W
+9.9%
1M
+8.4%
3M
+36.9%
6M
+77.4%
12M
+368.3%
Technicals
52W High
$16.80
52W Low
$3.19
50d MA
$14.17
200d MA
$9.31
RSI (14)
62.40
ATR (14)
$0.97
Beta
1.58
Avg Volume
4.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.60
High
$25.00
Low
$18.00
Median
$22.00
Data updated apr 26, 2026 11:00pm
· Source: financialmodelingprep.com